Long-term, open-label trial: Safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 1, 2012, Pages 37-47

  Brunner, G ^a   Athmann, C ^b   Schneider, A ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Center für Hepatogastroenterologie und HIV   (Germany)

^c Nycomed GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIN; PANTOPRAZOLE;

ADULT; ANEMIA; ARTICLE; ASTHENIA; CELL COUNT; CELL DENSITY; CLINICAL EXAMINATION; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROCHROMAFFIN LIKE CELL; FEMALE; GASTRIN BLOOD LEVEL; GASTRITIS; GASTROINTESTINAL ENDOSCOPY; GLOSSODYNIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PATIENT ASSESSMENT; PEPTIC ULCER; PERIPHERAL EDEMA; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; RISK ASSESSMENT; TREATMENT DURATION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ESOPHAGITIS, PEPTIC; FEMALE; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PEPTIC ULCER; PROTON PUMP INHIBITORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84861829850     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05106.x     Document Type: Article

References (24)

1. Bardhan KD, Bishop AE, Polak JM, et al,. Pantoprazole in severe acid-peptic disease: the effectiveness and safety of 5 years' continuous treatment. Dig Liver Dis 2005; 37: 10-22.
2. Brunner G, Harke U,. Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment Pharmacol Ther 1994; 8 (Suppl. 1): 59-64.
3. Larsson H, Hakanson R, Mattsson H, Ryberg B, Sundler F, Carlsson E,. Omeprazole: its influence on gastric acid secretion, gastrin and ECL cells. Toxicol Pathol 1988; 16: 267-72.
4. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al,. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018-22.
5. Genta RM,. Acid suppression and gastric atrophy: sifting fact from fiction. Gut 2009; 43: S35-8.
6. Klinkenberg-Knol EC, Nelis F, Dent J, et al,. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 661-9.
7. Lamberts R, Brunner G, Solcia E,. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion 2001; 64: 205-13.
8. Fujimoto K, Hongo M,. Safety and efficacy of long-term maintenance therapy with oral dose of rabeprazole 10 mg once daily in japanese patients with reflux esophagitis. Intern Med 2011; 50: 179-88.
9. Hirschowitz BI, Simmons J, Mohnen J,. Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study. Aliment Pharmacol Ther 2001; 15: 1795-806.
10. Dixon MF, Genta RM, Yardley JH, Correa P,. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-81.
11. Misiewicz JJ, Tytgat GNJ, Goodwin CS, et al,. The Sydney System: A new classification of gastritis. World Congress on Gastroenterology Working Party Reports. Sydney: Blackwell Science Publishing, 1990.
12. Fitton A, Wiseman L,. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996; 51: 460-82.
13. Cheer SM, Prakash A, Faulds D, Lamb HM,. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs 2003; 63: 101-33.
14. Lamberts R,. Morphological changes of the human gastric mucosa under long-term proton pump inhibitor therapy and their clinical relevance. Microsc Res Tech 2000; 48: 357-66.
15. Hirschowitz BI,. Clinical aspects of ECL-cell abnormalities. Yale J Biol Med 1998; 71: 303-10.
16. Solcia E, Fiocca R, Havu N, Dalvag A, Carlsson R,. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion 1992; 51: 82-92.
17. Klinkenberg-Knol EC, Festen HP, Jansen JB, et al,. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161-7.
18. Eissele R, Brunner G, Simon B, Solcia E, Arnold R,. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997; 112: 707-17.
19. Laine L, Ahnen D, McClain C, Solcia E, Walsh JH,. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 651-68.
20. Haber MM, Hunt B, Freston JW, et al,. Changes of gastric histology in patients with erosive oesophagitis receiving long-term lansoprazole maintenance therapy. Aliment Pharmacol Ther 2010; 32: 83-96.
21. Graham DY, Genta RM,. Long-term proton pump inhibitor use and gastrointestinal cancer. Curr Gastroenterol Rep 2008; 10: 543-7.
22. Stolte M, Meining A, Seifert E, Alexandridis T,. Treatment with lansoprazole also induces hypertrophy of the parietal cells of the stomach. Pathol Res Pract 2000; 196: 9-13.
23. Lundell L, Miettinen P, Myrvold HE, et al,. Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Gastroenterology 1999; 117: 319-26.
24. Malfertheiner P, Megraud F, O'Morain C, et al,. The European Helicobacter Study Group (EHSG). Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-81.